» Articles » PMID: 37757844

A Patient-Centered, Combination Intervention to Support Adherence to HIV Pre-exposure Prophylaxis During Pregnancy and Breastfeeding: A Randomized Pilot Study in Malawi

Abstract

Background: Daily oral pre-exposure prophylaxis (PrEP) can reduce HIV incidence in pregnant and breastfeeding women, but adherence is essential.

Methods: We conducted a pilot randomized trial to evaluate an intervention package to enhance antenatal and postnatal PrEP use in Lilongwe, Malawi. The intervention was based on patient-centered counseling adapted from previous PrEP studies, with the option of a participant-selected adherence supporter. Participants were locally eligible for PrEP and randomized 1:1 to intervention or standard counseling (ie, control) and followed for 6 months. Participants received the intervention package or standard counseling at enrollment, 1, 3, and 6 months. Adherence was measured through plasma and intracellular tenofovir concentrations and scored using a published algorithm. Our primary outcome was retention in care with concentrations consistent with 4-7 doses/week.

Results: From June to November 2020, we enrolled 200 pregnant women with the median gestational age of 26 (interquartile range: 19-33) weeks. Study retention was high at 3 months (89.5%) and 6 months (85.5%). By contrast, across the 2 time points, 32.8% of participants retained in the study had adherence scores consistent with 2-5 doses/week while 10.3% had scores consistent with daily dosing. For the composite primary end point, no substantial differences were observed between the intervention and control groups at 3 months (28.3% vs. 29.0%, probability difference: -0.7%, 95% confidence interval: -13.3%, 11.8%) or at 6 months (22.0% vs. 26.3%, probability difference: -4.3%, 95% confidence interval: -16.1%, 7.6%).

Conclusions: In this randomized trial of PrEP adherence support, retention was high, but less than one-third of participants had pharmacologically confirmed adherence of ≥4 doses/week. Future research should focus on antenatal and postnatal HIV prevention needs and their alignment across the PrEP continuum, including uptake, persistence, and adherence.

Citing Articles

Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission.

Njuguna I, Saidi F, Davey D, Chi B, Pintye J Front Reprod Health. 2024; 6:1382548.

PMID: 38689754 PMC: 11058988. DOI: 10.3389/frph.2024.1382548.

References
1.
Davies N, Heffron R . Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sex Health. 2018; 15(6):501-512. PMC: 6790372. DOI: 10.1071/SH18067. View

2.
Kinuthia J, Pintye J, Abuna F, Mugwanya K, Lagat H, Onyango D . Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2019; 7(1):e38-e48. PMC: 11498332. DOI: 10.1016/S2352-3018(19)30335-2. View

3.
Pyra M, Anderson P, Hendrix C, Heffron R, Mugwanya K, Haberer J . Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018; 32(13):1891-1898. PMC: 6061961. DOI: 10.1097/QAD.0000000000001922. View

4.
Thomson K, Hughes J, Baeten J, John-Stewart G, Celum C, Cohen C . Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners. J Infect Dis. 2018; 218(1):16-25. PMC: 5989601. DOI: 10.1093/infdis/jiy113. View

5.
Eldridge S, Chan C, Campbell M, Bond C, Hopewell S, Thabane L . CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016; 355:i5239. PMC: 5076380. DOI: 10.1136/bmj.i5239. View